Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study

Published:2021-11 Issue:11 Volume:21 Page:1539-1548
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Hyams Catherine,Marlow Robin,Maseko Zandile,King Jade,Ward Lana,Fox Kazminder,Heath Robyn,Tuner Anabella,Friedrich Zsolt,Morrison Leigh,Ruffino Gabriella,Antico Rupert,Adegbite David,Szasz-Benczur Zsuzsa,Garcia Gonzalez Maria,Oliver Jennifer,Danon Leon,Finn Adam

Funder

Bill and Melinda Gates Foundation

Medical Research Council

Pfizer

Engineering and Physical Sciences Research Council

Pfizer Inc Boulder

National Institute for Health Research

Janssen Pharmaceuticals

Alan Turing Institute

UK Research and Innovation

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference21 articles.

1. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine;Polack;N Engl J Med,2020

2. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting;Dagan;N Engl J Med,2021

3. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK;Voysey;Lancet,2021

4. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials;Voysey;Lancet,2021

5. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial;Ramasamy;Lancet,2021

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An extension of the Benefit Risk Assessment of VaccinEs (BRAVE) Toolkit to evaluate Comirnaty and Spikevax vaccination in the European Union;2024-08-09

2. RNAs in the diagnosis and treatment of major diseases;Chinese Science Bulletin;2024-08-01

3. COVID-19 vaccine updates for people under different conditions;Science China Life Sciences;2024-07-29

4. The landscape of the COVID-19 pandemic in Poland emerging from epidemiological and genomic data;Scientific Reports;2024-06-22

5. Analyzing factors affecting positivity in drive-through COVID-19 testing: a cross-sectional study;Virology Journal;2024-05-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3